search
Back to results

Primary Chemotherapy by BCNU-TMZ Combination in Newly Diagnosed Anaplastic Oligodendrocytic Tumors: Phase II Trial With Translational Molecular Analysis (TEMOBIC)

Primary Purpose

Oligodendroglioma; Oligoastrocytoma

Status
Completed
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
Bis-Chloroethyl-Nitroso-Urea (BCNU) withTemozolomide
Sponsored by
Assistance Publique Hopitaux De Marseille
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Oligodendroglioma; Oligoastrocytoma focused on measuring chemotherapy, BCNU-Temozolomide, radiotherapy

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Histologically proven oligodendroglioma or anaplastic oligoastrocytoma, newly diagnosed, resulting or not from a low grade glioma
  • Tumor with measurable contrast enhancement (at least 15 mm in diameter)
  • Surgical procedure limited to a biopsy or partial excision
  • In the event of partial excision, an early postoperative check-up (<72 hours) performed at best by MRI, if not by CT, is required.
  • Time between surgery and inclusion less than or equal to one and a half months (45 days)
  • Age> 18 years old; <70
  • Karnofsky index> 60
  • Stable or reduced dose of corticosteroids in the 15 days prior to inclusion
  • Polynuclear neutrophils> 1500; platelets> 100,000
  • Bilirubin <1.25 x UNL; SGOT, SGPT, PAL <2.5 x UNL
  • Absence of serious uncontrolled pathology
  • Patient having received and understood the information and having signed the consent

Exclusion Criteria:

  • Presence of GBM foci within the tumor
  • Absence of evaluable residue after surgery
  • Previous chemotherapy or radiotherapy
  • Unsatisfactory expected monitoring conditions
  • Pregnant or breastfeeding woman; lack of effective contraception if of childbearing age
  • History of malignant disease (with the exception of CIS of the cervix and basal cell cancer)
  • Contraindications related to the examination of the I.R.M.

Sites / Locations

  • Assistance Publique - Hôpitaux de Marseille

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment Arm

Arm Description

Administration of 6 cycles of chemotherapy

Outcomes

Primary Outcome Measures

Objective response rate of the BCNU-TMZ combination administered before radiotherapy
In oligodendrogliomas and anaplasic oligoastrocytomas as the first line of treatment
Objective response rate of the BCNU-TMZ combination administered before radiotherapy
In oligodendrogliomas and anaplasic oligoastrocytomas as the first line of treatment
Objective response rate of the BCNU-TMZ combination administered before radiotherapy
In oligodendrogliomas and anaplasic oligoastrocytomas as the first line of treatment
Objective response rate of the BCNU-TMZ combination administered before radiotherapy
In oligodendrogliomas and anaplasic oligoastrocytomas as the first line of treatment

Secondary Outcome Measures

Full Information

First Posted
February 10, 2021
Last Updated
February 11, 2021
Sponsor
Assistance Publique Hopitaux De Marseille
search

1. Study Identification

Unique Protocol Identification Number
NCT04755023
Brief Title
Primary Chemotherapy by BCNU-TMZ Combination in Newly Diagnosed Anaplastic Oligodendrocytic Tumors: Phase II Trial With Translational Molecular Analysis
Acronym
TEMOBIC
Official Title
Primary Chemotherapy by BCNU-TMZ Combination in Newly Diagnosed Anaplastic Oligodendrocytic Tumors: Phase II Trial With Translational Molecular Analysis
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Completed
Study Start Date
December 21, 2005 (Actual)
Primary Completion Date
March 15, 2009 (Actual)
Study Completion Date
December 15, 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique Hopitaux De Marseille

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The first-line treatment of anaplastic oligodendrogliomas, radiotherapy exclusive or combined with PCV, will be defined by the pending results of phase III of the EORTC. If the phase II study proposed here achieves its objective, it may help define a new treatment regimen that will be compared to the standard arm from phase III of the EORTC. In addition, this study, by prospectively testing the predictive value of 1p and 19q deletions and of REGF amplification, may allow characterization of patients using these markers. If validated, this characterization can constitute a key element in any therapeutic evaluation (patient stratification), and potentially a major tool for medical decision support in these tumors.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Oligodendroglioma; Oligoastrocytoma
Keywords
chemotherapy, BCNU-Temozolomide, radiotherapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
53 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment Arm
Arm Type
Experimental
Arm Description
Administration of 6 cycles of chemotherapy
Intervention Type
Drug
Intervention Name(s)
Bis-Chloroethyl-Nitroso-Urea (BCNU) withTemozolomide
Intervention Description
Chemotherapy (BCNU) will be delivered at Day 1. between day 1 and day 5, temolozomide will be administered . One cycle is planned every 6 weeks until 6 cycles.
Primary Outcome Measure Information:
Title
Objective response rate of the BCNU-TMZ combination administered before radiotherapy
Description
In oligodendrogliomas and anaplasic oligoastrocytomas as the first line of treatment
Time Frame
At the end of Cycle 2 (each cycle is 28 days)
Title
Objective response rate of the BCNU-TMZ combination administered before radiotherapy
Description
In oligodendrogliomas and anaplasic oligoastrocytomas as the first line of treatment
Time Frame
At the end of Cycle 4 (each cycle is 28 days)
Title
Objective response rate of the BCNU-TMZ combination administered before radiotherapy
Description
In oligodendrogliomas and anaplasic oligoastrocytomas as the first line of treatment
Time Frame
At the end of Cycle 6 (each cycle is 28 days)
Title
Objective response rate of the BCNU-TMZ combination administered before radiotherapy
Description
In oligodendrogliomas and anaplasic oligoastrocytomas as the first line of treatment
Time Frame
1 month after radiotherapy

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically proven oligodendroglioma or anaplastic oligoastrocytoma, newly diagnosed, resulting or not from a low grade glioma Tumor with measurable contrast enhancement (at least 15 mm in diameter) Surgical procedure limited to a biopsy or partial excision In the event of partial excision, an early postoperative check-up (<72 hours) performed at best by MRI, if not by CT, is required. Time between surgery and inclusion less than or equal to one and a half months (45 days) Age> 18 years old; <70 Karnofsky index> 60 Stable or reduced dose of corticosteroids in the 15 days prior to inclusion Polynuclear neutrophils> 1500; platelets> 100,000 Bilirubin <1.25 x UNL; SGOT, SGPT, PAL <2.5 x UNL Absence of serious uncontrolled pathology Patient having received and understood the information and having signed the consent Exclusion Criteria: Presence of GBM foci within the tumor Absence of evaluable residue after surgery Previous chemotherapy or radiotherapy Unsatisfactory expected monitoring conditions Pregnant or breastfeeding woman; lack of effective contraception if of childbearing age History of malignant disease (with the exception of CIS of the cervix and basal cell cancer) Contraindications related to the examination of the I.R.M.
Facility Information:
Facility Name
Assistance Publique - Hôpitaux de Marseille
City
Marseille
ZIP/Postal Code
13005
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Primary Chemotherapy by BCNU-TMZ Combination in Newly Diagnosed Anaplastic Oligodendrocytic Tumors: Phase II Trial With Translational Molecular Analysis

We'll reach out to this number within 24 hrs